CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer
PA Jänne, D Planchard, K Kobayashi… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …
Management of brain metastases: a review of novel therapies
Brain metastases (BMs) represent the most common intracranial tumors in adults, and most
commonly originate from lung, followed by breast, melanoma, kidney, and colorectal cancer …
commonly originate from lung, followed by breast, melanoma, kidney, and colorectal cancer …
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
J Moes-Sosnowska, A Szpechcinski… - Tumor …, 2023 - content.iospress.com
The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
Introduction Brain metastases commonly occur in patients with non-small cell lung cancer
(NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation …
(NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation …
Design, synthesis and antitumor activity evaluation of 4, 6, 7-trisubstituted quinazoline derivatives containing benzothiazole moiety
F Yu, Y Xu, H Wang, L Chi, X Si, C Gao, H Dai… - Medicinal Chemistry …, 2023 - Springer
Abstract A series of novel 4, 6, 7-trisubstituted quinazoline derivatives containing
benzothiazole moiety were designed, synthesized and evaluated for their antitumor activity …
benzothiazole moiety were designed, synthesized and evaluated for their antitumor activity …
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
T Okuno, T Isobe, Y Tsubata - Clinical & Experimental Metastasis, 2024 - Springer
Lung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal
glands, and other organs; however, the occurrence of brain metastases is the most common …
glands, and other organs; however, the occurrence of brain metastases is the most common …
Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung …
H Qi, Y Hou, Z Zheng, M Zheng, Q Qiao, Z Wang, X Sun… - BMC cancer, 2024 - Springer
Background Predicting short-term efficacy and intracranial progression-free survival (iPFS)
in epidermal growth factor receptor gene mutated (EGFR-mutated) lung adenocarcinoma …
in epidermal growth factor receptor gene mutated (EGFR-mutated) lung adenocarcinoma …
ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR
A Liu, H Xie, F Tian, P Bai, H Weng, Y Liu, W Liu… - …, 2023 - Am Heart Assoc
BACKGROUND: Cardiac hypertrophy and subsequent heart failure impose a considerable
burden on public health worldwide. Impaired protein degradation, especially endo-lysosome …
burden on public health worldwide. Impaired protein degradation, especially endo-lysosome …
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
T Landre, JB Assié, K Chouahnia… - Expert Review of …, 2024 - Taylor & Francis
Introduction A tyrosine-kinase inhibitor (TKI) is indicated as first-line treatment for patients
with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor–receptor …
with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor–receptor …
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins …
Background: Adenocarcinoma of the lung is the most common type of lung cancer, and it is
characterized by distinct cellular and molecular features. It occurs when abnormal lung cells …
characterized by distinct cellular and molecular features. It occurs when abnormal lung cells …